| Halasa, Natasha |
NCT02860039: High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant |
|
|
| Active, not recruiting | 2 | 170 | US | Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza | 12/21 | 09/24 | | |
NCT04613206: High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients |
|
|
| Recruiting | 2 | 396 | US | High Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone High Dose, Standard Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone | Vanderbilt University Medical Center, Northwestern University Feinberg School of Medicine, University of Alabama at Birmingham, University of Washington | Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant | 12/24 | 04/25 | | |
NCT05215327: High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients |
|
|
| Recruiting | 2 | 270 | US | High Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone High Dose, Standard Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone | Vanderbilt University Medical Center, Northwestern University Feinberg School of Medicine, University of Alabama at Birmingham, University of Washington, Duke University | Immunization; Infection, Transplantation Infection, Influenza | 07/27 | 12/27 | | |
PSOT, NCT05947071: High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients |
|
|
| Not yet recruiting | 2 | 312 | US | Standard Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone, High Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone High Dose | National Institute of Allergy and Infectious Diseases (NIAID), Children's Hospital Medical Center, Cincinnati, Lucile Packard Children's Hospital, University of Pittsburgh, Ann & Robert H Lurie Children's Hospital of Chicago, Baylor College of Medicine, Children's Mercy Hospital Kansas City, Children's Healthcare of Atlanta | Immunization; Infection, Transplantation Infection, Influenza | 07/27 | 09/27 | | |
NCT04520659: Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age |
|
|
| Active, not recruiting | 1 | 81 | US | RSV LID/ΔM2-2/1030s, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi Pasteur, a Sanofi Company | RSV Infection | 06/24 | 12/24 | | |
| Completed | N/A | 244 | US | SARS-CoV-2 and/or MIS-C Exposure, Exposure: Severe Acute Respiratory Syndrome Coronavirus 2 Infection and/or Multisystem Inflammatory Syndrome in Children diagnosis | National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Clinical Trials in Organ Transplantation in Children | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C), Coronavirus Disease 2019 (COVID-19) | 03/23 | 03/23 | | |
NCT03924219: CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients |
|
|
| Active, not recruiting | N/A | 120 | US | CMV T cell Immunity Assay | Vanderbilt University Medical Center, ViraCor Laboratories | Heart Transplant Infection, Kidney Transplant Infection, Liver Transplant Infection, CMV | 07/24 | 12/24 | | |
